Stewart J W, McGrath P J, Liebowitz M R, Harrison W, Quitkin F, Rabkin J G
Arch Gen Psychiatry. 1985 Dec;42(12):1148-53. doi: 10.1001/archpsyc.1985.01790350022005.
An algorithm for transcribing Research Diagnostic Criteria diagnoses for depressive disorders to similar categories in the DSM-III was applied to 103 depressed outpatients previously diagnosed by Research Diagnostic Criteria. All had Hamilton Depression Rating Scale scores of 18 or less. Among 64 patients completing a six-week, double-blind study comparing desipramine hydrochloride with placebo, desipramine was significantly more effective than placebo in patients with DSM-III major depression but not in those with dysthymic disorder. Among patients with major depression, a significant drug-placebo response difference was demonstrated even in those without melancholia. These findings support the clinical usefulness of the DSM-III in the treatment of depressed outpatients. Independent of DSM-III diagnosis, however, evidence of panic attacks seemed to identify patients who benefited from desipramine therapy. This suggests that the DSM-III hierarchy, which excludes consideration of panic in patients with major depression, may require revision.
一种将研究诊断标准中抑郁症的诊断转录为《精神疾病诊断与统计手册》第三版（DSM - III）类似类别的算法，应用于103名先前由研究诊断标准诊断为抑郁症的门诊患者。所有患者汉密尔顿抑郁量表评分均为18分或更低。在64名完成一项为期六周的双盲研究（比较盐酸去甲丙咪嗪与安慰剂）的患者中，去甲丙咪嗪在患有DSM - III重度抑郁症的患者中比安慰剂显著更有效，但在患有心境恶劣障碍的患者中并非如此。在重度抑郁症患者中，即使在没有忧郁症的患者中也显示出显著的药物 - 安慰剂反应差异。这些发现支持了DSM - III在治疗抑郁症门诊患者中的临床实用性。然而，独立于DSM - III诊断之外，惊恐发作的证据似乎能识别出从去甲丙咪嗪治疗中获益的患者。这表明排除对重度抑郁症患者惊恐发作考虑的DSM - III分级可能需要修订。
